KRAS and colorectal cancer: <b>Conclusions:</b> The monitoring of resistance mutations in <i>KRAS</i> using ctDNA during the treatment of <i>KRAS</i> wild-type advanced colorectal cancers can detect the emergence of resistant clones prior to clinical progression.